Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

(HealthDay News) — More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American ...

The researchers found that postpartum depression prevalence doubled during the study period, increasing from 9.4% in 2010 to 19.0% in 2021. (HealthDay News) — Diagnosis of postpartum depression ...

Credit: Endo, Inc At this time, there have been no reports of adverse events related to this recall. While the blister strips ...

Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...

Seventy-six items achieved consensus, including indications for LDOM versus topical minoxidil, dosing for adults and teens, contraindications ...

Miplyffa was approved in September 2024 based on data from a clinical trial that showed arimoclomol plus miglustat slowed NPC disease progression.